---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017572"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:01:04.004837+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Virios reports Q3 net loss $2.6M, cash $9.8M, advances IMC-1 to Phase 3 based on post-hoc FORTRESS analysis

## Summary
- Net loss of $2.6M ($0.28 per share) for Q3 2022 vs $4.1M ($0.49) in Q3 2021.
- Cash totaled $9.8M as of Sep 30, 2022; company expects to fund operations through end of 2023.
- Post-hoc FORTRESS analysis shows significant pain reduction in fibromyalgia patients naive to prior trials/treatment.
- Company plans to meet with FDA to discuss advancing IMC-1 into Phase 3 development.
- Raised $5M in September 2022 equity capital to support IMC-1 development and working capital.

## SEC filing metadata
- accession: 0001558370-22-017572
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837022017572/0001558370-22-017572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837022017572/tmb-20221114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017572
- JSON: https://secwatch.observer/filing/0001558370-22-017572.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017572.txt

## Key facts
- Earnings Releases
  Dogwood Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income $2.6 million, EPS $0.28 basic and diluted net loss per share.
  - Period: the third quarter ended September 30, 2022
  - Net income: $2.6 million
  - EPS: $0.28 basic and diluted net loss per share
  - Result: reported results
  source text: Net loss for the third quarter ended September 30, 2022 was $2.6 million, or $0.28 basic and diluted net loss per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818844/000155837022017572/0001558370-22-017572-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.